Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results

THE WOODLANDS, Texas, March 16, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq: RPRX ) today announced financial results for the fourth quarter and year ended December 31, 2014.

Liquidity and Capital Resources

The Company had cash and cash equivalents of approximately $46.6 million as of December 31, 2014 as compared to $75.8 million as of December 31, 2013. Net cash of approximately $29.3 million was used in operating activities during the year ended December 31, 2014 as compared to $25.3 million for the year ended December 31, 2013. The major use of cash during 2014 was to fund the Company's clinical development programs and associated administrative costs. No cash was used in investing activities during 2014. Cash provided by financing activities during 2014 was $147,000 due to the exercise of 23,334 stock options for cash.

Financial Results

Net loss for the three month period ended December 31, 2014, was ($7.4) million, or ($0.31) per share, as compared to a net loss of ($7.3) million, or ($0.32) per share, for the same period in 2013. The net loss for the twelve month period ended December 31, 2014, was ($32.5) million, or ($1.39) per share, as compared to a net loss of ($28.5) million, or ($1.37) per share, for 2013. The increase in net loss for the three month period ended December 31, 2014 as compared to the same period in 2013 was primarily due to increased payroll and benefits, partially offset by a decreased clinical development expenses related to Androxal® and Proellex®. The increase in net loss for the twelve month period ended December 31, 2014 as compared to 2013 was primarily due to increased expenses in clinical development related to Androxal ® , payroll and benefits, non-cash stock based compensation and professional services costs. 

While preparing its financial statements for the year ended December 31, 2014, the Company identified a prior period error related to its accounting for patent costs. As disclosed in prior filings, historically the Company had capitalized patent related costs associated with its drug candidates, Androxal® and Proellex®. However, the Company has now concluded that these costs should have been expensed as research and development costs since the related products were, at the time the costs were incurred, in the development phase and had not been approved by the FDA.  The Company concluded this error was not material individually or in the aggregate to any of the prior reporting periods, and therefore, no restatements of previously issued financial statements were necessary. As such, revisions for the prior periods are reflected in the financial statements herein, and will be reflected in future filings containing such information.         

Research and development ("R&D") expenses increased 15%, or approximately $3.5 million, to $27.1 million for the year ended 2014 as compared to $23.7 million for 2013. The increase in R&D expenses for 2014 as compared to 2013 was primarily due to an increase of $2.4 million in clinical development expenses related to the Phase 3 studies for Androxal ® . Payroll and benefits expenses increased for 2014 as compared to 2013 by $405,000 due to increased headcount and salaries. Included in payroll and benefits expenses is a charge for non-cash stock based compensation of $1.9 million for 2014 as compared to $1.8 million for 2013. Additionally, operating and occupancy expenses increased $608,000 for 2014 as compared to 2013 due to increases in legal expenses and costs associated with our patent portfolio.

General and administrative ("G&A") expenses increased 13%, or approximately $619,000, to $5.4 million for the year ended 2014 as compared to $4.8 million for 2013. Payroll and benefits expenses increased 35%, or approximately $873,000, to $3.4 million for the year ended 2014 as compared to $2.5 million for 2013. Included in payroll and benefits expense is a charge for non-cash stock based compensation expense of $1.9 million for the year ended 2014 as compared to $1.3 million for 2013. Additionally, salaries for 2014 were $1.4 million as compared to $1.1 million for 2013. G&A operating and occupancy expense decreased 11%, or approximately $254,000, to $2.0 million for 2014 as compared to $2.3 million for 2013. The decrease was primarily due to a decrease in professional services costs.

Interest income was $9,000 for both years ended December 31, 2014 and 2013.

As of December 31, 2014, the Company had 24,276,173 shares of common stock outstanding.

About Repros Therapeutics Inc. ®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Any such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including the ability to have success in the clinical development of the Company's technologies, the reliability of interim results to predict final study outcomes, the ability to protect the Company's intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .

REPROS THERAPEUTICS INC. AND SUBSIDIARY
 
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
 
  Three Months Ended Twelve Months Ended
  December 31, December 31,
  2014 2013 2014 2013
         
Revenues        
Interest income  $ 3  $ 4  $ 9  $ 9
Total revenues  3  4  9  9
         
Expenses        
Research and development  5,771  5,953  27,107  23,657
General and administrative  1,678  1,365  5,437  4,818
Total expenses  7,449  7,318  32,544  28,475
         
Net loss  $ (7,446)  $ (7,314)  $ (32,535)  $ (28,466)
         
Net loss per share - basic and diluted  $ (0.31)  $ (0.32)  $ (1.39)  $ (1.37)
         
Weighted average shares used in loss per share calculation:        
Basic  24,234  23,012  23,432  20,808
Diluted  24,234  23,012  23,432  20,808
         
         
CONSOLIDATED BALANCE SHEETS    
(in thousands)    
     
  December 31, December 31,    
  2014 2013    
         
         
Cash and cash equivalents  $ 46,620  $ 75,807    
Other currents assets  289  189    
Fixed assets (net)  32  75    
Total assets  $ 46,941  $ 76,071    
         
Accounts payable and accrued expenses   $ 2,924  $ 3,552    
Stockholders' equity  44,017  72,519    
Total liabilities and stockholders' equity  $ 46,941  $ 76,071    

Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 46

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Music City San Francisco: A New Chapter for Local Artists

Updated Category News Views 307

Exciting Grand Opening of Music City San Francisco Rudy Colombini, a well-known figure in the local music scene, is making waves with his ambitious project, Music City San Francisco. This unique venue spans an impressive 29,000 square feet and is designed to rejuvenate San Francisco's status as a vibrant musical hub. Festival Kicks Off at the Grand Opening The festivities...

Continue Reading
Amplify Classroom Revolutionizes K-12 Teaching Experience

Updated Category News Views 890

Amplify Unveils Innovative Teaching Platform for Educators Amplify has introduced its latest initiative, Amplify Classroom, aimed at enhancing the educational experience for teachers and students alike. This platform is designed to provide educators with a comprehensive suite of tools and resources to support interactive and impactful teaching. A Large Library of Free...

Continue Reading
Countries Leading the Global Economy in 2026

Updated Category Economy Views 228

The world's economic map is not static. Rankings shift as countries grow, stumble, or restructure, and the metrics used to measure strength produce very different pictures depending on what you prioritize. Nominal GDP, purchasing power parity, GDP per capita, and innovation indices each tell a different part of the story. For a trader or investor, understanding which...

Continue Reading
RYVYL's Strategic Move in Pre-funded Asset Sale Negotiation

Updated Category News Views 272

RYVYL Inc. Ends Negotiations on Asset Sale Restructuring - Buyer intends to close the pre-funded asset sale - RYVYL Inc. (NASDAQ: RVYL), renowned for its innovative payment transaction solutions, has recently made a significant strategic decision concerning its RYVYL EU subsidiary. The company has ceased all discussions regarding the restructuring of the pre-funded asset...

Continue Reading
Investors Urged to Join James Hardie Class Action Lawsuit

Updated Category News Views 152

Class Action Lawsuit Against James Hardie Industries plc In a significant legal move, a class action lawsuit has been initiated against James Hardie Industries plc (NYSE: JHX). The lawsuit brings attention to concerns over potential inaccuracies in the company’s financial disclosures. The law firm Robbins Geller Rudman & Dowd LLP is leading the charge, encouraging...

Continue Reading